Ultivue
Edit

Ultivue

http://www.ultivue.com/
Last activity: 22.08.2024
Active - Reference to
Categories: AppBioTechCultureEnergyTechFastInformationJobResearchTechnologyWebsite
Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company's technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA. Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue’s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy. Open Positions Ultivue provides unique opportunities for talented individuals to bring all of themselves--their passion, expertise and creativity--to bear on collectively solving problems that matter. For the full list of open positions and to apply please visit our website https://www.ultivue.com/careers. When submitting job application, make sure to submit both a resume and a cover letter.
Followers
6.4K
Mentions
18
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $97.15M
Founded date: 2015

Investors 2

Funding Rounds 4

DateSeriesAmountInvestors
27.04.2021Series D$50M-
27.06.2019Series C$22M-
24.01.2018Series B$20MARCH Ventu...
13.10.2015Series A$5.15M-

Mentions in press and media 18

DateTitleDescription
22.08.2024Accelerating Translational Research with High-Performance Automated InSituPlex® Assays, Upcoming Webinar Hosted by Xtalkswww.ultivue.com In this free webinar, learn how the InSituPlex biomarker detection assays facilitate high-confidence biomarker analysis with enhanced sensitivity and specificity. Attendees will discover the simplicity of the workflow while ...
11.06.2024Investigating Cell Therapy Efficacy Mechanisms in Solid Tumors by Spatial Immunophenotyping, Upcoming Webinar Hosted by Xtalkswww.ultivue.com In this free webinar, learn how spatial immunophenotyping assays are being used to understand the whole tumor microenvironment in patient biopsy samples. Attendees will learn how multiplex immunofluorescence (mIF) assays can...
30.06.2022Importance of Spatial Distribution Insight from Clinical Biopsies, Upcoming Webinar Hosted by XtalksToday, spatial biology is finally giving researchers much needed contextual information resolving cells and biomarkers. TORONTO (PRWEB) June 30, 2022 Current immuno-oncology research is revealing diagnostic, prognostic and predictive cell s...
05.08.2021Fluidigm : Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 MillionBase business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corp...
27.04.2021Ultivue : Announces $50M Financing RoundUltivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Ser...
27.06.2019Ultivue Raises $22 Million in Series C FundingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Series C funding led by...
27.06.2019Ultivue Raises $22M in Series C FundingUltivue, a Cambridge, Mass.-based leader in tissue biomarker identification and quantification assays for translational and pathology research labs, closed a $22M Series C funding. The round was led by new investor Northpond Ventures with p...
27.06.2019Ultivue Raises $22 Million in Series C Funding-
24.01.2018Ultivue Completes $20M Series B Funding CAMBRIDGE, MA, Ultivue has announced that it has closed a $20 million Series B funding round led by existing investor ARCH Venture Partners. >> Click here for more funding data on Ultivue >> To export Ultivue funding data to...
23.01.2018ARCH Venture Leads $20M Series B for UltivueCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, has announced today that it has closed a $20 million Series B funding round led by exi...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In